The combination of CJC-1295 No DAC and Ipamorelin represents a dual-acting growth hormone secretagogue system widely investigated in preclinical models for inducing selective, pulsatile somatotropin release. By simultaneously targeting the growth hormone-releasing hormone receptor (GHRH-R) and the growth hormone secretagogue receptor (GHS-R) without significantly elevating baseline cortisol or prolactin, this combination serves as a primary reference standard in endocrine laboratory research.
The combination of CJC-1295 No DAC and Ipamorelin represents a dual-acting growth hormone secretagogue system widely investigated in preclinical models for inducing selective, pulsatile somatotropin release. By simultaneously targeting the growth hormone-releasing hormone receptor (GHRH-R) and the growth hormone secretagogue receptor (GHS-R) without significantly elevating baseline cortisol or prolactin, this combination serves as a primary reference standard in endocrine laboratory research.
In endocrine and molecular research, the co-administration of CJC-1295 No DAC (frequently designated as Mod GRF 1-29) and Ipamorelin is studied for its synergistic activation of pituitary somatotrophs. Rather than relying on a single signaling pathway, this combination engages two distinct receptor populations to evaluate downstream growth hormone (GH) transcription, translation, and exocytosis.
Preclinical investigations demonstrate that combining a synthetic growth hormone-releasing hormone (GHRH) analog with a selective ghrelin receptor agonist generates a greater GH response than either peptide administered in isolation. Researchers investigating pituitary axis kinetics utilize the cjc no dac ipamorelin blend to model biomimetic, pulsatile hormone release profiles under controlled laboratory parameters.
CJC-1295 No DAC is a tetrasubstituted 29-amino acid peptide derivative of natural GHRH (1-29). The amino acid modifications at positions 2, 8, 15, and 27 (D-Ala, Gln, Ala, and Leu, respectively) were engineered to enhance enzymatic stability against dipeptidyl peptidase IV (DPP-IV) degradation while preserving affinity for the GHRH receptor.
Unlike extended-half-life variants containing the Drug Affinity Complex (DAC), CJC-1295 No DAC lacks the maleimidopropionic acid linker that binds serum albumin. Consequently, in vitro data indicate that CJC No DAC exhibits a rapid clearance profile with a plasma half-life of approximately 30 minutes in animal models. This brief systemic duration preserves natural circadian pituitary refractory periods, making it an optimal subject for evaluating natural secretagogue pulses.
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) classified as a second-generation growth hormone secretagogue. It acts as a potent and selective agonist at the growth hormone secretagogue receptor 1a (GHS-R1a), mimicking the endogenous ligand ghrelin.
In cell culture assays and rodent models, Ipamorelin binds to GHS-R1a to initiate intracellular calcium mobilization via the phospholipase C (PLC) and inositol trisphosphate (IP3) pathways. A defining characteristic of Ipamorelin in preclinical literature is its exceptional receptor selectivity: unlike earlier hexapeptides in its class, Ipamorelin does not induce significant transcription or secretion of adrenocorticotropic hormone (ACTH), cortisol, or prolactin, even at supramaximal experimental concentrations.
The primary objective of investigating CJC No DAC and Ipamorelin in tandem is to characterize the biochemical synergy resulting from simultaneous GHRH-R and GHS-R activation. GHRH-R stimulation increases intracellular cyclic adenosine monophosphate (cAMP) via adenylate cyclase, promoting protein kinase A (PKA) signaling. Concurrently, GHS-R stimulation elevates intracellular free ionic calcium via the protein kinase C (PKC) pathway.
Preclinical studies suggest that when these two intracellular cascades are activated simultaneously in pituitary somatotrophs, the net exocytosis of pre-stored GH vesicles is amplified beyond additive expectation. This dual-pathway mechanism models natural physiological release without inducing continuous, non-physiological secretagogue exposure, allowing investigators in our research library to examine non-refractory GH signaling cascades.
A critical benchmark in secretagogue research is maintaining target specificity to prevent confounding experimental variables. First-generation growth hormone secretagogues frequently display off-target activity, triggering stress-axis activation or galactagogue signaling that can complicate data interpretation in physiological studies.
Comparative in vitro assays indicate that the combination of CJC No DAC and Ipamorelin maintains strict selectivity for the somatotropic axis. In canine and rodent models, researchers observed that serum aldosterone, cortisol, and prolactin levels remained baseline during active GH transactivation. This isolated endocrine response makes the pair an ideal tool for studying somatotropin-specific downstream cellular outcomes, such as hepatic IGF-1 transcription and peripheral nitrogen retention.
Evaluating secretagogue combinations requires contrasting their pharmacokinetic and pharmacodynamic profiles against other established compounds in the growth hormone secretagogues category. Differences in half-life, receptor binding, and off-target activity dictate which model is appropriate for specific laboratory objectives.
When compared to continuous-release analogs like CJC-1295 With DAC, the CJC No DAC variant avoids continuous baseline GHRH-R stimulation, preserving receptor sensitivity and physiological pulsatility. Furthermore, compared to historical secretagogues such as GHRP-2 or GHRP-6, Ipamorelin exhibits a significantly superior selectivity profile with negligible cortisol or prolactin release. Alternatively, single-chain options like Sermorelin offer classic GHRH-R activation but lack the amplified response generated by secondary GHS-R co-stimulation.
Proper reconstitution technique is critical to preserve the secondary structure and biological activity of lyophilized CJC No DAC and Ipamorelin during in vitro experimentation. Standard laboratory procedures mandate working under a laminar flow hood using sterile techniques to prevent bacterial contamination or peptide degradation.
Lyophilized cakes should be reconstituted using laboratory-grade bacteriostatic water (0.9% benzyl alcohol) or sterile normal saline depending on the assay requirements. The liquid diluent should be introduced gently along the glass vial wall, allowing the solvent to naturally wicks into the cake. Gentle swirling is recommended; mechanical shaking must be strictly avoided as shear forces can induce peptide aggregation or denaturation. Full dissolution typically occurs within 30 to 60 seconds at ambient room temperature.
Lyophilized formulations of CJC No DAC and Ipamorelin demonstrate excellent long-term chemical stability when stored under appropriate thermodynamic conditions. Unopened vials stored in a desiccated environment at -20°C remain stable for up to 24 months, while short-term storage at 2°C to 8°C is acceptable for up to 90 days without measurable degradation.
Once reconstituted into aqueous solution, peptide stability decreases due to susceptibility to hydrolysis and oxidation. Reconstituted aliquots must be maintained at 2°C to 8°C and utilized within 21 to 28 days. For extended experimental timelines, reconstituted solutions should be aliquoted into single-use polypropylene microtubes and stored at -80°C to avoid repeated freeze-thaw cycles, which degrade secondary peptide conformations.
Rigorous analytical characterization is essential to ensure that experimental secretagogues yield reproducible, publication-grade data. Institutional laboratories must verify both structural identity and physical purity before initiating cell culture or animal assays.
PX1 Research subjects every production lot to dual-stage analytical testing. High-Performance Liquid Chromatography (RP-HPLC) is utilized to confirm purity levels exceeding 99.0%, while Electrospray Ionization Mass Spectrometry (ESI-MS) confirms exact molecular weight matching theoretical sequence mass. Additionally, all lots undergo chromogenic Limulus Amebocyte Lysate (LAL) assay testing to verify that endotoxin content remains strictly below <0.01 EU/mg, preventing cell culture toxicity or non-specific inflammatory responses in animal models.
Securing consistent, high-purity research materials is a prerequisite for reliable preclinical experimentation. PX1 Research operates fully compliant domestic manufacturing facilities located in California and Arizona, adhering to ISO 9001 and ISO 17025 laboratory quality management systems.
Every batch of CJC No DAC and Ipamorelin is issued a lot-specific, downloadable Certificate of Analysis (COA) detailing HPLC chromatograms, mass spectra, and endotoxin quantitation. Institutional facilities requiring high-volume supplies for long-term study protocols can access dedicated enterprise procurement options through our wholesale lab portal. All orders ship same-day from domestic US facilities under controlled temperature packaging.
What is the primary operational difference between CJC No DAC and CJC With DAC?
CJC No DAC (Mod GRF 1-29) lacks the Drug Affinity Complex linker, resulting in a short half-life (~30 minutes) that models discrete, pulsatile GH pulses. CJC With DAC binds serum albumin to extend plasma half-life to several days, producing continuous elevated baseline levels.
Why are CJC No DAC and Ipamorelin combined in preclinical research?
The combination engages two distinct signaling pathways simultaneously: CJC No DAC activates the GHRH receptor via cAMP/PKA, while Ipamorelin activates the GHS-R1a receptor via IP3/Calcium pathways. Co-activation yields a synergistic, amplified release of somatotropin greater than the sum of individual compound effects.
Does Ipamorelin elevate cortisol or prolactin levels in laboratory models?
In vitro and in vivo studies confirm that Ipamorelin is highly selective for GHS-R1a and does not cause statistically significant elevations in ACTH, cortisol, or prolactin, even when evaluated at high experimental doses.
What diluent should be used to reconstitute CJC No DAC and Ipamorelin for laboratory assays?
Bacteriostatic water (0.9% benzyl alcohol) is standard for multi-use laboratory applications to prevent microbial growth. For specific cell culture assays where benzyl alcohol is contraindicated, sterile 0.9% sodium chloride or phosphate-buffered saline (PBS) may be utilized.
How should reconstituted peptide solutions be stored?
Reconstituted solutions must be refrigerated at 2°C to 8°C and used within 21 to 28 days. For long-term preservation of reconstituted liquid, store aliquots at -80°C and avoid repeated freeze-thaw cycles.
What purity standard is guaranteed for PX1 Research compounds?
All PX1 Research compounds are verified at ≥99% purity by RP-HPLC and mass spectrometry. Each lot includes a fully transparent Certificate of Analysis showing exact analytical testing outputs.
What is the endotoxin limit threshold for PX1 Research peptides?
Every lot is LAL-tested to ensure endotoxin levels measure below <0.01 EU/mg, safeguarding against non-specific inflammatory signaling or cell culture cytotoxicity during preclinical trials.
How does this combination compare to Sermorelin in secretagogue research?
Sermorelin targets only the GHRH receptor, producing a standard single-pathway response. Combining CJC No DAC with Ipamorelin introduces secondary GHS-R activation, yielding significantly higher GH release per molar unit while maintaining comparable selectivity.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.